A 14-day pulse of PLX5622 modifies α-synucleinopathy in preformed fibril-infused aged mice of both sexes

A 14-day pulse of PLX5622 modifies α-synucleinopathy in preformed fibril-infused aged mice of both sexes

Reactive microglia are observed with aging and in Lewy body disorders, including within the olfactory bulb of men with Parkinson's disease. However, the functional impact of microglia in these disorders is still debated. Resetting these reactive cells by a brief dietary pulse of the colony-stim...

Full description

Bibliographic Details
Main Authors:	Tarun N. Bhatia, Anuj S. Jamenis, Muslim Abbas, Rachel N. Clark, Kristin M. Miner, Manisha N. Chandwani, Roxanne E. Kim, William Hilinski, Lauren A. O'Donnell, Kelvin C. Luk, Yejie Shi, Xiaoming Hu, Jun Chen, Jeffrey L. Brodsky, Rehana K. Leak
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Neurobiology of Disease
Subjects:	Microglia Lewy body Synuclein Dementia Neurodegeneration Parkinson's disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996123002115

Similar Items

Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy
by: Scott C. Vermilyea, et al.
Published: (2022-07-01)

Possible Alterations in β-Synuclein, the Non-Amyloidogenic Homologue of α-Synuclein, during Progression of Sporadic α-Synucleinopathies
by: Makoto Hashimoto, et al.
Published: (2012-09-01)

Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy
by: Allison J. Schaser, et al.
Published: (2020-08-01)

Putting PLX5622 into perspective: microglia in central nervous system viral infection
by: Alanna G Spiteri, et al.
Published: (2023-01-01)

Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
by: Arati Tripathi, et al.
Published: (2021-12-01)

Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis
by: Nils Mein, et al.
Published: (2023-12-01)

Calcium: alpha-synuclein interactions in alpha-synucleinopathies
by: Alexandre N. Rcom-H’cheo-Gauthier1, et al.
Published: (2016-12-01)

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
by: Omar El-Agnaf, et al.
Published: (2017-08-01)

Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-Synucleinopathies
by: Ichiro Kawahata, et al.
Published: (2022-06-01)

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
by: Naomi P. Visanji, et al.
Published: (2019-09-01)

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies
by: Zhiguo Sun, et al.
Published: (2024-03-01)

Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies
by: Chao Peng, et al.
Published: (2018-01-01)

Significant Sex Differences in the Efficacy of the CSF1R Inhibitor-PLX5622 on Rat Brain Microglia Elimination
by: Aviv Sharon, et al.
Published: (2022-05-01)

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
by: Megan F. Duffy, et al.
Published: (2018-09-01)

Development and characterization of a non-human primate model of disseminated synucleinopathy
by: Alberto J. Rico, et al.
Published: (2024-03-01)

Clinical application of prion-like seeding in α-synucleinopathies: Early and non-invasive diagnosis and therapeutic development
by: Jiaqi Li, et al.
Published: (2022-10-01)

14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model
by: Rachel Underwood, et al.
Published: (2021-01-01)

Norovirus Intestinal Infection and Lewy Body Disease in an Older Patient with Acute Cognitive Impairment
by: Manuel Moreno-Valladares, et al.
Published: (2022-07-01)

PLX5622 Reduces Disease Severity in Lethal CNS Infection by Off-Target Inhibition of Peripheral Inflammatory Monocyte Production
by: Alanna G. Spiteri, et al.
Published: (2022-03-01)

Fishing for synucleinopathy models
by: Suzita Mohd Noor, et al.
Published: (2022-03-01)

Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve
by: Norihito Uemura, et al.
Published: (2018-05-01)

Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies
by: P.G. Foulds, et al.
Published: (2012-01-01)

Vitamin A potently destabilizes preformed α-synuclein fibrils in vitro: Implications for Lewy body diseases
by: Kenjiro Ono, et al.
Published: (2007-02-01)

Cell-Type Specific Changes in DNA Methylation of SNCA Intron 1 in Synucleinopathy Brains
by: Jeffrey Gu, et al.
Published: (2021-04-01)

Neuropathological evidence of body-first vs. brain-first Lewy body disease
by: Per Borghammer, et al.
Published: (2021-12-01)

Neuropathology and molecular diagnosis of Synucleinopathies
by: Shunsuke Koga, et al.
Published: (2021-12-01)

Effects of α-synuclein on axonal transport
by: Laura A. Volpicelli-Daley
Published: (2017-09-01)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
by: Ilaria Poggiolini, et al.
Published: (2021-05-01)

Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
by: Junghwan Shin, et al.
Published: (2020-01-01)

Neurons and Glia Interplay in α-Synucleinopathies
by: Panagiota Mavroeidi, et al.
Published: (2021-05-01)

Apolipoprotein E Gene in α-Synucleinopathies: A Narrative Review
by: Ioannis Liampas, et al.
Published: (2024-02-01)

Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
by: Martin Kallab, et al.
Published: (2018-07-01)

Development of α-Synuclein Real-Time Quaking-Induced Conversion as a Diagnostic Method for α-Synucleinopathies
by: Takehiro Nakagaki, et al.
Published: (2021-09-01)

α-Synuclein fibril-induced paradoxical structural and functional defects in hippocampal neurons
by: Jessica M. Froula, et al.
Published: (2018-05-01)

Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
by: David J. Koss, et al.
Published: (2022-07-01)

Pyrroloquinoline quinone influences intracellular alpha-synuclein aggregates
by: Elizabeth Mountford, et al.
Published: (2023-01-01)

Inflammation in dementia with Lewy bodies
by: Jay Amin, et al.
Published: (2022-06-01)

Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
by: Bradley R. Groveman, et al.
Published: (2018-02-01)

Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies
by: Christopher Hatton, et al.
Published: (2020-07-01)

Glucocerebrosidase involvement in Parkinson Disease and other Synucleinopathies
by: Maria Rosario Almeida
Published: (2012-04-01)